This inventor holds 2 USPTO granted patents. Top assignee: Università Degli Studi Di Roma "Tor Vergata". Active years: 2013-2015.
Company Filing History:
Years Active: 2013-2015
Title: Innovator Spotlight: Elisabetta Volpe
Introduction
Elisabetta Volpe, an accomplished inventor based in Rome, Italy, has made significant contributions to the field of immunology. With a total of two patents to her name, she is recognized for her innovative approaches to treating infections through the development of immunoregulator compounds.
Latest Patents
Among her latest patents, the most notable invention relates to sphingosine derivative compounds, specifically D-erythro-sphingosine 1-phosphate (S1P). These compounds serve as immunomodulators in the microbicidal treatment of bacterial infections. The uniqueness of her invention lies in its ability to stimulate macrophagic Phospholipase D (PLD). Additionally, this patent encompasses pharmaceutical compositions utilizing these sphingosine derivatives as well as diagnostic methods for their preparation. It also outlines methods for inducing or restoring the microbicidal activity in macrophages, aimed at monitoring phagocytosis efficiency and evaluating the therapeutic effectiveness of candidate microbicides.
Career Highlights
Elisabetta Volpe is affiliated with the Università degli Studi di Roma “Tor Vergata,” where her research and innovations continue to drive forward the boundaries of medical science. Her dedication to developing compounds that enhance immune responses highlights her role as a leading figure in her field.
Collaborations
Throughout her career, Elisabetta has collaborated with esteemed colleagues, including Maurizio Fraziano and Sanjay Kumar Garg. These partnerships reflect a shared commitment to advancing research in immunology and developing effective treatments for infectious diseases.
Conclusion
Elisabetta Volpe’s innovative contributions and her ongoing research hold promise for significant advancements in immune therapies. Her work not only reflects her dedication to science but also offers hope for improved treatments for bacterial infections. As her research progresses, it will be exciting to see her future innovations continue to shape the landscape of immunology.